treatment

Kim Kardashian grapples with a health scare that hits close to home in a new trailer for “The Kardashians.”

The reality star and fashion mogul reveals in the reality series’ Season 8 trailer released Thursday that she has been diagnosed with esophagitis.

“I have something called esophagitism,” Kim tells a stylist in the trailer. The Skims founder is then shown in a hospital bed in a series of clips, one in which it appears she’s being wheeled into a procedure. While it’s unclear who is speaking to Kim, someone off-screen says, “Didn’t your father … isn’t it what he died of?”

If esophagitis is left untreated, there’s a risk of developing Barrett‘s esophagus condition, in which the cells lining the esophagus are damaged from acid reflux, according to Mayo Clinic. The condition raises the risk of cancer that starts in the esophagus, which is called esophageal cancer.

Kim’s dad, famed attorney Robert Kardashian, died in September 2003 at the age of 59. He had been diagnosed with esophageal cancer just months before his death.

“I can’t, it makes me want to cry,” Kim’s mom Kris Jenner says in the trailer, alluding to the frightening diagnosis.

Esophagitis is inflammation of the tissues that line the esophagus, per the Mayo Clinic. The condition can be painful and make swallowing difficult, and it can cause chest pain. While there are a variety of causes for the condition, the trailer does not reveal which has contributed to Kim’s case.

Kim Kardashian in “The Kardashians” in 2022.

(Photo from Hulu)

Treatment for the health issue can vary and depends upon the severity of tissue damage and the cause. Without proper treatment, the lining of the esophagus, which is the tube that carries food and water to your stomach, can be badly damaged. This can lead to more serious health issues including scarring and narrowing of the esophagus, or even tearing in the esophagus.

When detected early, however, the condition is considered treatable.

Sept. 4 (UPI) — The Food and Drug Administration on Friday approved a new, targeted breast cancer drug for patients who become resistant to hormone therapy.

The drug, camizestrant, was approved under the FDA’s accelerated approval program.

It acts on ESR1 mutations, which are acquired resistances that tumors may develop during treatment for metastatic breast cancer.

“Women living with metastatic breast cancer face an uphill battle as their tumors continuously evolve to escape treatment,” acting FDA Commissioner Kyle Diamantas said in a statement. “We owe them every weapon in our arsenal.”

“Today’s approval delivers a win to these patients by granting them a targeted therapy designed specifically to overcome resistance, giving them more time before their disease progresses.”

Dr. Angelo de Claro, director of the FDA’s Oncology Center of Excellence, said, “I commend both the FDA and the sponsor for their commitment to advancing cancer care and securing this accelerated approval.”

“This marks the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA (ctDNA) before imaging tests show that the disease is progressing,” he added.

“But additional evidence is needed to confirm clinical benefit.”

Aug. 26 (UPI) — On Wednesday, the U.S. Food and Drug Administration announced its approval of Rasonque, a new treatment option for people with advanced pancreatic cancer.

A tablet taken once a day, the medication targets forms of a protein called RAS, which is a key driver of tumor growth in many patients with pancreatic adenocarcinoma, the most common form of the cancer, the FDA said. This form of cancer develops in cells lining the ducts of the pancreas.

“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer,” said Kyle Diamantas, acting commissioner of the FDA. “It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible.”

A press release from the FDA said the approval demonstrates the agency’s “commitment to moving with urgency, reducing unnecessary delays and advancing innovative treatments.”

Rasonque has been approved for adults who have metastatic pancreatic adenocarcinoma who have received at one least one prior systemic therapy or those who are not candidates for multiagent systemic therapy.

About 90% to 95% of the new cases of pancreatic cancer diagnosed in the United States each year are this form, the FDA said, citing the National Cancer Institute. Johns Hopkins Medicine also said “the vast majority” of pancreatic cancer diagnoses are this form.

In a clinical trial, the new treatment improved median overall survival to 13.2 months from 6.7 months with standard chemotherapy, the FDA said.

“This drug showed unprecedented results in an area of high unmet need,” said Angelo de Claro, director of the FDA’s Oncology Center of Excellence.

The agency granted this approval to Revolution Medicines Inc.